DesheNOMICS 15.2.22

Seller's Remorse? Will BH come back to TEVA?

Teva (NYSE: TEVA) Q4 2021 Deshe Analysis

Teva's latest report is a clear example of Deshe's value to stock analysts and investors. Teva published their Q4 report in February 9th. Many investors sold, causing a significant drop in Teva's stock price. But as the US market 'woke up', sophisticated investors who knew how to properly analyze the report and took the time to really analyze it took advantage of the information, causing the stock to rise by ~10%.

Deshe's AI-based equity research report broke down and explained according to each significant fundamental category (value, growth, and cash flow) and explained why Teva earned its Buy ranking.

Today, news broke that Berkshire Hathaway exited Teva throughout Q4 at a loss (link) and are no longer shareholders. Now, being able to read Deshe's analysis report, we'll see if they change their mind.

Deshe Analytics?covers +37,000 global stocks, investors can easily and instantly compare these results to Teva's peers to get an objective and relative sense of an opportunity.

Deshe Analytics?does the heavy lifting and sophisticated financial analysis for you, instantly giving you easy-to-understand insights. We uniquely cover nearly all US & global Micro-Cap, Small-Cap, Mid-Cap, and Large-cap stocks that Wall Street and other equity research and investment firms ignore by leveraging quantitative, fundamental, and alternative data.

And additional languages (Arabic, Dutch, Spanish, and more) are coming soon.

Access?Deshe Analytics?and find the companies Wall Street doesn’t want you to know about.

DISCLAIMER:

Deshe Analytics?does not own (actual or beneficial) shares in any securities mentioned above.?

This report is intended for general guidance and information purposes only. Under no circumstances intended to be used or considered financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer?click here.